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Introduction {#sec005}
============

Hepatocellular carcinoma (HCC) is the third leading cause of death in patients with malignancies in the world \[[@pone.0129000.ref001], [@pone.0129000.ref002]\]. Curative liver resection (CLR) provides early HCC patients with a radical therapy although overall prognosis post surgery is still an issue of great concern. The Cancer of the Liver Italian Program (CLIP) scoring system is a widely accepted prognostic model for patients with HCC. To date, it remains controversial whether it is the best model for predicting the prognosis in patients who underwent CLR for HCC \[[@pone.0129000.ref003], [@pone.0129000.ref004]\].

Up until now, there are two principal modified CLIP scoring systems. These include the modified CLIP using protein induced by vitamin K absence or antagonist II (PIVKA-II) \[[@pone.0129000.ref005]\] and the model of end-stage liver disease (MELD)-based CLIP \[[@pone.0129000.ref006]\]. Unfortunately, neither of the scoring systems has been validated in other independent medical centers. Meanwhile, only the modified CLIP using PIVKA-II is aimed at patients who undergo CLR for HCC, and PIVKA-IIis not a commonly used factor that is available for all HCC patients. There is therefore a great need to develop a reliable prognostic model for HCC patients who received CLR with widely available variables.

The aim of this study was to construct and validate a modified CLIP scoring system specific to patients who underwent CLR for HCC in two large separated cohorts involving five independent tertiary medical centers so as to produce accurate prognostic information after surgery.

Materials and Methods {#sec006}
=====================

Study Design {#sec007}
------------

In this study, we established and validated a modified CLIP scoring system named Surgery-Specific CLIP (SSCLIP) by recruiting patients who received CLR for HCC from five separated tertiary medical centers (training cohort: the First Affiliated Hospital of Wenzhou Medical University from January 2005 to June 2010; validation cohort: the Second Affiliated Hospital of Wenzhou Medical University; Jinhua People's Hospital; Shaoxing People's Hospital; Wenzhou Central Hospital; from September 2008 to January 2014).

The start date of the follow-up was the date of CLR. The follow-up periods were 46.3 ± 25.2 months in the training cohort and 24.7 ± 15.9 months in the validation cohort. Written informed consent was obtained from each patient included in the study and the research protocol of the study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University, the Second Affiliated Hospital of Wenzhou Medical University, Jinhua People's Hospital, Shaoxing People's Hospital and Wenzhou Central Hospital.

Inclusion and Exclusion Criteria {#sec008}
--------------------------------

Patients who received CLR for suspected HCC were selected. The diagnosis of HCC was verified by post-operative interpretation of pathological analyses and patients who met the following criteria were excluded: 1) non-HCC diseases according to postoperative pathological diagnosis; 2) not the first primary cancer; 3) multiple primary cancer; 4) distant metastasis; 5) previous history of hepatic resection; 6) previous history of percutaneous ethanol injection, radiofrequency, transarterial chemoembolization or liver transplantation.

Data Collection and Follow-up {#sec009}
-----------------------------

Patient demographic information, HCC etiology, clinical and laboratory data within the week before CLR were extracted from medical records. Demographic information included age and gender. Clinical parameters included hepatic encephalopathy (HE), history of alcohol abuse, liver cirrhosis (LC) and ascites. HE was diagnosed according to West-Haven criteria \[[@pone.0129000.ref007]\]. Ascites were detected by physical examination and confirmed by ultrasonic test, computerized tomography (CT) or magnetic resonance imaging (MRI). LC was detected by ultrasound, CT or MRI, and confirmed by histological examination. Laboratory parameters included total bilirubin (TB), direct bilirubin (DB), albumin (ALB), alanine aminotransferase (ALT), aspartate aminotranferase (AST), alkaline phosphatase, γ-glutamyl transferase (γ-GT), blood glucose, serum creatinine (Cr), uric acid, serum sodium, prothrombin time (PT), prothrombin time activity (PTA), international normalized ratio (INR), white blood cell count, platelet count, and hepatitis B virus (HBV) serologic markers (Abbott, AXSYM). Hepatitis C virus (HCV) antibody was detected using ELISA (IEGAN, Freedom evolyzer/150). Tumor characteristics including the number of tumor nodules, the diameter of the largest nodule and portal vein thrombosis were observed during the surgery. Microvascular invasion (MVI) was observed in postoperative pathologic examination. Alpha-fetoprotein (AFP) level within the week before CLR was collected.

Patients were followed-up every 3 months after surgery. At follow-up, CT or MRI imaging was performed and the level of AFP was assessed. Information on death was obtained from the social security death index and medical records along with notifications from the family of the deceased were used to supplement the information to ensure complete capture of all decedents.

Scoring Systems and Prognostic Models {#sec010}
-------------------------------------

The model of end-stage liver disease (MELD) score was calculated according to the Malinchoc formula: MELD = 9.57 × ln(creatinine \[mg/dL\]) + 3.78 × ln(bilirubin \[mg/dL\]) + 11.2 × ln(INR) + 6.43 × (aetiology: 0 if cholestatic or alcoholic, 1 otherwise) \[[@pone.0129000.ref008]\]. Okuda score, which included tumor size, ascite, TB, ALB, was assessed and divide into 3 stages according to the standard criteria \[[@pone.0129000.ref009]\]. CTP score, which included HE, ascite, TB, ALB and PT, was assessed and divide into 3 stages according to the standard criteria \[[@pone.0129000.ref010]\]. Original CLIP score, which included CTP stage, tumor morphology, AFP, and portal vein thrombosis, was assessed according to standard criteria \[[@pone.0129000.ref011]\]. MELD-based CLIP score, which replaced the CTP score with the MELD score in the original CLIP, was calculated according to Huo et al \[[@pone.0129000.ref006]\].

Construction of the SSCLIP {#sec011}
--------------------------

In the training cohort, we performed univariate Cox proportional hazards regression analysis for determining the association of demographic, clinical, laboratory parameters and tumor characteristics with prognosis and survival time. Then, those covariables with univariate significance (P \< 0.05) were included in a multivariate Cox proportional hazards regression to identify independent predictors for the prognosis of the patients with HCC. These independent predictors were added into the original CLIP to construct the SSCLIP in which receiver operating characteristics (ROC) analysis or recognized standard was used to identify possible predictive cutoff values for the predictors. Different sets of cutoff values and possible combinations were tested and optimal combination was chose in terms of outcome evaluation.

To assess 12-month and 36-month prognostic efficiency of the SSCLIP, the area under the receiver operating characteristic curve (AUROC) was calculated both in the training and validation cohorts. Comparison of the AUROC between the SSCLIP and other models was performed using the method of Hanley and McNeil \[[@pone.0129000.ref012]\]. The survival distributions of different score categories were assessed by the Kaplan-Meier method and compared using a log rank test. The standard indices of validity, such as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) were calculated according to the ROC results.

Statistical Analysis {#sec012}
--------------------

Continuous variables were expressed as mean ± standard deviation (SD) and categorical values were expressed by absolute and relative frequencies. Differences in continuous variables were analyzed using Mann-Whitney U test. The Chi-square test or the Fisher's exact test was used for categorical data as appropriate. For all analyses, a P value of \< 0.05 was considered statistically significant. Statistical analysis was performed using the IBM SPSS Statistics Version 19.0 (IBM Corp, Armonk, NY, USA) and MedCalc version 13.0 (MedCalc Software, Ostend, Belgium).

Results {#sec013}
=======

Baseline Characteristics of Included Patients {#sec014}
---------------------------------------------

2215 patients received CLR for suspected HCC were enrolled in the study. After exclusion of those patients who did not meet the inclusion criteria ([Fig 1](#pone.0129000.g001){ref-type="fig"}), 668 patients (281 in the training cohort and 387 in the validation cohort) were finally included. Characteristics collected were presented in [Table 1](#pone.0129000.t001){ref-type="table"}. Mean age of included patients was 55.8 ± 11.3 years in the training cohort and 57.0 ± 10.9 years in the validation cohort and the patients were predominantly men (86.1% in the training cohort and 84.5% in the validation cohort). HBV was the predominant etiology in both cohorts (48.0% and 71.0%), followed by superinfection of HBV and HCV (36.2% and 12.8%). Both cohorts did not include patients with HE. The majority of patients had a single tumor (87.2% and 89.0%), with tumor diameter of 50.1 ± 33.5 mm and 47.4 ± 31.2 mm in the training and validation cohorts respectively.

![A flow diagram of study participants.\
\*the Second Affiliated Hospital of Wenzhou Medical University, Jinhua People's Hospital, Shaoxing People's Hospital, Wenzhou Central Hospital; HCC, hepatocellular carcinoma; PEI, Percutaneous ethanol injection; RF, radiofrequency; TACE, Transarterial chemoembolization.](pone.0129000.g001){#pone.0129000.g001}

10.1371/journal.pone.0129000.t001

###### Characteristics of Hepatocellular Carcinoma Patients Who Received Curative Liver Resection, Stratified by Cohort.

![](pone.0129000.t001){#pone.0129000.t001g}

  Variables                          Training cohort (n = 281)   Validation cohort (n = 387)   P-value
  ---------------------------------- --------------------------- ----------------------------- ----------
  **Demographic parameters**                                                                   
   Age (years)                       55.8 ± 11.3                 57.0 ± 10.9                   0.156
   Male gender, n (%)                242 (86.1%)                 327 (84.5%)                   0.560
  **Clinical parameters**                                                                      
   Ascites, n (%)                    23 (9.9%)                   32 (9.6%)                     0.013
   Liver cirrhosis, n (%)            121 (50.8%)                 147 (43.8%)                   0.390
  **Etiology**                                                                                 
   HBV, n (%)                        131 (48.0%)                 272 (71.0%)                   \< 0.001
   HCV, n (%)                        3 (1.1%)                    3 (0.8%)                      0.375
   Alcohol, n (%)                    21 (7.7%)                   31 (8.1%)                     0.259
   HBV + HCV, n (%)                  99 (36.2%)                  49 (12.8%)                    \< 0.001
   Other, n (%)                      19 (7.0%)                   28 (7.3%)                     0.277
  **Laboratory parameters**                                                                    
   Total bilirubin (μmol/L)          15.6 ± 21.0                 14.0 ± 19.1                   0.028
   Direct bilirubin (μmol/L)         6.1 ± 14.8                  6.8 ± 20.4                    0.882
   Albumin (g/L)                     40.6 ± 5.8                  39.9 ± 5.7                    0.098
   ALT (IU/L)                        58.2 ± 78.0                 53.6 ± 78.0                   0.092
   AST (IU/L)                        67.7 ± 92.5                 58.0 ± 118.0                  0.069
   Alkaline phosphatase (IU/L)       106.8 ± 53.9                110.1 ± 91.0                  0.735
   γ-GT (IU/L)                       87.4 ± 80.0                 98.7 ± 153.4                  0.334
   Blood glucose (mmol/L)            6.4 ± 2.9                   6.6 ± 2.9                     0.047
   Creatinine (μmol/L)               69.8 ± 32.1                 69.6 ± 22.6                   0.651
   Uric acid (μmol/L)                294.6 ± 85.2                304.9 ± 91.9                  0.199
   Serum sodium (mmol/L)             142.6 ± 24.1                140.3 ± 2.8                   \< 0.001
   PT (s)                            14.3 ± 1.3                  14.2 ± 1.3                    0.159
   PTA (%)                           86.5 ± 13.0                 87.8 ± 13.7                   0.127
   INR                               1.5 ± 5.8                   1.4 ± 4.9                     0.056
   White blood cell (10^9^/L)        6.4 ± 6.4                   5.9 ± 5.5                     0.096
   Platelet (10^9^/L)                135.3 ± 64.6                140.6 ± 63.9                  0.244
   HBsAg positive (%)                229 (83.3%)                 307 (79.9%)                   0.280
   HBsAb positive (%)                36 (17.1%)                  68 (17.7%)                    0.842
   HBeAg positive (%)                56 (26.4%)                  97 (25.3%)                    0.757
   HBeAb positive (%)                158 (74.9%)                 300 (78.1%)                   0.369
   HBcAb positive (%)                204 (96.2%)                 367 (95.6%)                   0.703
  **Tumor Characteristics**                                                                    
   Alpha fetoprotein (ng/ml)         2388.9 ± 9330.8             1677.9 ± 6751.4               0.396
   Number of nodules                                                                           
    1                                225 (87.2%)                 331 (89.0%)                   0.479
    2                                19 (7.3%)                   30 (8.1%)                     0.817
    3                                12 (4.7%)                   9 (2.4%)                      0.134
    ≥ 4                              2 (0.8%)                    2 (0.5%)                      0.701
   Size of the largest nodule (mm)   50.1 ± 33.5                 47.4 ± 31.2                   0.280
   Portal vein thrombosis, n (%)     2 (0.7%)                    10 (3.0%)                     0.058
   Microvascular invasion, n (%)     110 (39.1%)                 88 (23.0%)                    \< 0.001
  **MELD score**                     8.0 ± 2.3                   8.4 ± 3.6                     0.041
  **Okuda score**                    0.5 ± 0.6                   0.4 ± 0.6                     0.883
  **Okuda stage**                                                                              
   I, n (%)                          140 (61.4%)                 225 (68.0%)                   0.910
   II, n (%)                         87 (38.2%)                  101 (30.5%)                   0.664
   III, n (%)                        1 (0.4%)                    5 (1.5%)                      0.999
  **CTP score**                      5.7 ± 1.1                   5.6 ± 1.2                     0.984
  **CTP stage**                                                                                
   A, n (%)                          183 (81.7%)                 272 (82.4%)                   0.177
   B, n (%)                          38 (17.0%)                  51 (15.5%)                    0.126
   C, n (%)                          3 (1.3%)                    7 (2.1%)                      0.263
  **CLIP score**                     1.1 ± 1.2                   1.1 ± 1.2                     0.999

**NOTE**. HBV, hepatitis B virus; HCV, hepatitis C virus; ALT, alanine aminotranferase; AST, aspartate aminotranferase; γ-GT, γ-glutamyl transferase; PT, prothrombin time; PTA, prothrombin time activity; INR, international normalized ratio; HBsAg, hepatitis B s antigen; HBsAb, hepatitis B s antibody; HBeAg, hepatitis B e antigen; HBeAb, hepatitis B e antibody; HBcAb, hepatitis B c antibody; MELD, model for end-stage liver disease; CTP, Child-Turcotte-Pugh; CLIP, Cancer of The Liver Italian Program.

[Table 2](#pone.0129000.t002){ref-type="table"} shows that patients who survived in the training cohort had a younger age (54.2 years vs 57.3 years, P = 0.041), a lower rate of MVI (28.5% vs 50.3%, P \< 0.001), a higher ALB (41.6 g/L vs 39.7 g/L, P = 0.002), a tendency of higher PTA (87.4% vs 85.6% P = 0.289), a lower Okuda score (0.3 vs 0.5, P = 0.005), a lower CTP score (5.4 vs 5.7, P = 0.013), and a lower CLIP score (0.8 vs 1.3, P = 0.019). These conditions were similar to the validation cohort, except for PTA, which was significantly higher in survivors in the validation cohort (88.8% vs 83.5%, P = 0.002), and age (56.7 years vs 57.9 years, P = 0.431).

10.1371/journal.pone.0129000.t002

###### Characteristics of Hepatocellular Carcinoma Patients Who Received Curative Liver Resection, Stratified by Mortality.
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  Variables                          Training cohort (n = 281)[\*](#t002fn002){ref-type="table-fn"}   Validation cohort (n = 387)[^\#^](#t002fn003){ref-type="table-fn"}                                                   
  ---------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------------- ---------- ----------------- ------------------ ----------
  **Demographic parameters**                                                                                                                                                                                               
   Age (years)                       54.2 ± 11.4                                                      57.3 ± 11.2                                                          0.041      56.7 ± 11.1       57.9 ± 10.3        0.431
   Male gender, n (%)                114 (85.1%)                                                      128 (87.1%)                                                          0.628      267 (84.2%)       60 (85.7%)         0.756
  **Clinical parameters**                                                                                                                                                                                                  
   Ascites, n (%)                    2 (1.8%)                                                         7 (6.1%)                                                             0.100      25 (9.0%)         7 (13.0%)          0.366
   Liver cirrhosis, n (%)            33 (28.9%)                                                       57 (47.1%)                                                           0.004      123 (44.1%)       24 (42.1%)         0.784
  **Etiology**                                                                                                                                                                                                             
   HBV, n (%)                        62 (47.7%)                                                       69 (48.2%)                                                           0.698      242 (77.1%)       30 (43.5%)         \< 0.001
   HCV, n (%)                        3 (2.3%)                                                         0 (0%)                                                               0.999      3 (1.0%)          0 (0%)             0.999
   Alcohol, n (%)                    7 (5.4%)                                                         14 (9.8%)                                                            0.236      23 (7.3%)         8 (11.6%)          0.023
   HBV + HCV, n (%)                  50 (38.5%)                                                       49 (34.3%)                                                           0.633      25 (7.9%)         24 (34.8%)         \< 0.001
   Other, n (%)                      8 (6.1%)                                                         11 (7.7%)                                                            0.670      21 (6.7%)         7 (10.1%)          0.038
  **Laboratory parameters**                                                                                                                                                                                                
   Total bilirubin (μmol/L)          12.5 ± 6.9                                                       18.5 ± 28.0                                                          0.008      13.1 ± 12.3       18.0 ± 36.4        0.677
   Direct bilirubin (μmol/L)         4.0 ± 2.4                                                        7.9 ± 20.0                                                           0.001      4.1 ± 2.2         9.7 ± 29.2         0.139
   Albumin (g/L)                     41.6 ± 5.8                                                       39.7 ± 5.6                                                           0.002      40.2 ± 5.5        38.2 ± 6.4         0.011
   ALT (IU/L)                        54.3 ± 70.1                                                      61.8 ± 84.6                                                          0.076      49.6 ± 67.3       71.5 ± 113.5       0.011
   AST (IU/L)                        51.7 ± 66.8                                                      82.3 ± 109.4                                                         \< 0.001   53.6 ± 118.8      82.3 ± 111.0       0.003
   Alkaline phosphatase (IU/L)       95.3 ± 31.0                                                      118.3 ± 68.1                                                         0.101      106.9 ± 94.4      128.8 ± 65.0       \< 0.001
   γ-GT (IU/L)                       72.6 ± 74.6                                                      102.2 ± 83.0                                                         0.003      98.7 ± 163.3      98.9 ± 72.6        0.007
   Blood glucose (mmol/L)            6.6 ± 2.9                                                        6.3 ± 2.9                                                            0.164      6.6 ± 2.8         6.7 ± 3.1          0.366
   Creatinine (μmol/L)               67.9 ± 23.1                                                      71.5 ± 38.5                                                          0.239      70.5 ± 22.8       65.2 ± 21.7        0.011
   Uric acid (μmol/L)                291.9 ± 81.3                                                     297.1 ± 88.8                                                         0.757      307.5 ± 89.3      293.3 ± 103.0      0.149
   Serum sodium (mmol/L)             141.1 ± 2.8                                                      143.9 ± 33.1                                                         0.602      140.3 ± 2.8       140.5 ± 2.8        0.330
   PT (s)                            14.2 ± 1.2                                                       14.4 ± 1.3                                                           0.262      14.1 ± 1.3        14.7 ± 1.4         0.001
   PTA (%)                           87.4 ± 12.8                                                      85.6 ± 13.1                                                          0.289      88.8 ± 13.6       83.5 ± 13.7        0.002
   INR                               1.1 ± 0.2                                                        1.8 ± 8.0                                                            0.184      1.1 ± 0.1         2.5 ± 11.6         \< 0.001
   White blood cell (10^9^/L)        5.6 ± 2.0                                                        7.1 ± 8.6                                                            0.188      5.5 ± 2.3         7.9 ± 11.9         0.110
   Platelet (10^9^/L)                131.1 ± 59.2                                                     139.1 ± 69.1                                                         0.552      139.9 ± 62.8      143.5 ± 69.5       0.878
   HBsAg positive (%)                111 (84.7%)                                                      118 (81.9%)                                                          0.536      255 (81.0%)       52 (75.4%)         0.294
   HBsAb positive (%)                15 (13.9%)                                                       21 (20.4%)                                                           0.210      51 (16.2%)        17 (24.6%)         0.096
   HBeAg positive (%)                24 (22.2%)                                                       32 (30.8%)                                                           0.158      74 (23.5%)        23 (33.3%)         0.088
   HBeAb positive (%)                83 (76.9%)                                                       75 (72.8%)                                                           0.499      245 (77.8%)       55 (79.7%)         0.725
   HBcAb positive (%)                105 (97.2%)                                                      99 (95.2%)                                                           0.678      299 (94.9%)       68 (98.6%)         0.315
  **Tumor Characteristics**                                                                                                                                                                                                
   Alpha fetoprotein (ng/ml)         1764.3 ± 8995.1                                                  2940.0 ± 9616.7                                                      0.846      1248.7 ± 5038.0   3612.1 ± 11565.2   0.136
   Number of nodules                                                                                                                                                                                                       
    1                                112 (90.3%)                                                      113 (84.3%)                                                          0.461      279 (90.3%)       52 (82.5%)         0.149
    2                                9 (7.3%)                                                         10 (7.5%)                                                            0.840      23 (7.4%)         7 (11.1%)          0.284
    3                                3 (2.4%)                                                         9 (6.7%)                                                             0.109      5 (1.6%)          4 (6.4%)           0.034
    ≥ 4                              0 (0%)                                                           2 (1.5%)                                                             0.999      2 (0.7%)          0 (0%)             0.999
   Size of the largest nodule (mm)   47.1 ± 30.0                                                      53.1 ± 35.7                                                          0.238      45.3 ± 29.3       57.7 ± 37.7        0.010
   Portal vein thrombosis, n (%)     0 (0%)                                                           1 (0.9%)                                                             1.000      7 (2.5%)          3 (5.6%)           0.447
   Microvascular invasion, n (%)     37 (28.5%)                                                       73 (50.3%)                                                           \< 0.001   48 (15.3%)        40 (58.0%)         \< 0.001
  **MELD score**                     7.9 ± 1.6                                                        9.0 ± 5.2                                                            0.121      7.9 ± 2.0         9.4 ± 6.7          0.006
  **Okuda score**                    0.3 ± 0.5                                                        0.5 ± 0.6                                                            0.005      0.4 ± 0.6         0.6 ± 0.7          0.013
  **Okuda stage**                                                                                                                                                                                                          
   I, n (%)                          83 (76.1%)                                                       67 (58.8%)                                                           0.006      196 (70.8%)       29 (53.7%)         0.052
   II, n (%)                         26 (23.9%)                                                       47 (41.2%)                                                           0.006      77 (27.8%)        24 (44.4%)         0.015
   III, n (%)                        0 (0%)                                                           0 (0%)                                                               \-         4 (1.4%)          1 (1.9%)           0.644
  **CTP score**                      5.4 ± 0.8                                                        5.7 ± 1.1                                                            0.013      5.6 ± 1.2         6.1 ± 1.5          0.002
  **CTP stage**                                                                                                                                                                                                            
   A, n (%)                          100 (93.5%)                                                      92 (82.9%)                                                           0.120      234 (84.5%)       38 (71.7%)         0.087
   B, n (%)                          7 (6.5%)                                                         17 (15.3%)                                                           0.040      38 (13.7%)        13 (24.5%)         0.042
   C, n (%)                          0 (0%)                                                           2 (1.8%)                                                             0.999      5 (1.8%)          2 (3.8%)           0.292
  **CLIP score**                     0.8 ± 1.0                                                        1.3 ± 1.3                                                            0.019      1.0 ± 1.2         1.5 ± 1.5          0.011

**NOTE**.

\*The follow-up period of training cohort was 46.3 ± 25.2 months;

^\#^The follow-up period of validation cohort was 24.7 ± 15.9 months; HBV, hepatitis B virus; HCV, hepatitis C virus; ALT, alanine aminotranferase; AST, aspartate aminotranferase; γ-GT, γ-glutamyl transferase; PT, prothrombin time; PTA, prothrombin time activity; INR, international normalized ratio; HBsAg, hepatitis B s antigen; HBsAb, hepatitis B s antibody; HBeAg, hepatitis B e antigen; HBeAb, hepatitis B e antibody; HBcAb, hepatitis B c antibody; MELD, model for end-stage liver disease; CTP, Child-Turcotte-Pugh; CLIP, Cancer of The Liver Italian Program.

Construction of the SSCLIP {#sec015}
--------------------------

To identify independent predictors of mortality, the univariate and multivariate Cox proportional hazard analyses were performed in the training cohort ([Table 3](#pone.0129000.t003){ref-type="table"}). In univariate Cox proportional hazards analysis, we found that age, LC, TB, DB, ALB, AST, alkaline phosphatase, γ-GT, PT, PTA, white blood cell count, number of tumor nodules, portal vein thrombosis and MVI were significantly associated with mortality (all P \< 0.05). The above variables with univariate significance were then entered into the multivariate Cox proportional hazards regression analyses to select independent predictors. Age (HR = 1.075, 95%CI: 1.019--1.135, P = 0.009), ALB (HR = 0.804, 95%CI: 0.681--0.950, P = 0.011), PTA (HR = 0.856, 95%CI: 0.751--0.975, P = 0.020) and MVI (HR = 19.852, 95%CI: 2.203--178.917, P = 0.008) were found to be independent predictors.

10.1371/journal.pone.0129000.t003

###### Univariate and Multivariate Cox Proportional Hazards Regression Analyses of the Associations between Mortality and Variables in the Training Cohort.
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  Variables                          Univariate analysis   Multivariate analysis                                                               
  ---------------------------------- --------------------- ----------------------- ---------------- ------- -------- -------- ---------------- -------
  **Demographic parameters**                                                                                                                   
   Age (years)                       0.014                 1.015                   1.000--1.029     0.045   0.073    1.075    1.019--1.135     0.009
   Gender                            -0.044                0.957                   0.591--1.550     0.859                                      
  **Clinical parameters**                                                                                                                      
   Ascites                           0.333                 1.395                   0.937--2.078     0.101                                      
   Liver cirrhosis                   0.537                 1.711                   1.195--2.449     0.003                                      
  **Laboratory parameters**                                                                                                                    
   Total bilirubin (μmol/L)          0.005                 1.005                   1.001--1.010     0.027                                      
   Direct bilirubin (μmol/L)         0.007                 1.007                   1.001--1.013     0.030                                      
   Albumin (g/L)                     -0.060                0.942                   0.916--0.969     0.001   -0.218   0.804    0.681--0.950     0.011
   ALT (IU/L)                        0.001                 1.001                   1.000--1.003     0.126                                      
   AST (IU/L)                        0.003                 1.003                   1.001--1.005     0.006                                      
   Alkaline phosphatase (IU/L)       0.009                 1.009                   1.005--1.013     0.001                                      
   γ-GT (IU/L)                       0.003                 1.003                   1.001--1.005     0.017                                      
   Blood glucose (mmol/L)            -0.010                0.990                   0.929--1.054     0.744                                      
   Creatinine (μmol/L)               0.003                 1.003                   0.997--1.008     0.330                                      
   Uric acid (μmol/L)                0.001                 1.001                   0.999--1.002     0.620                                      
   Serum sodium (mmol/L)             0.003                 1.003                   0.998--1.008     0.233                                      
   PT (s)                            0.133                 1.142                   1.011--1.290     0.033                                      
   PTA (%)                           -0.014                0.986                   0.974--0.999     0.030   -0.155   0.856    0.751--0.975     0.020
   INR                               0.007                 1.007                   0.987--1.028     0.475                                      
   White blood cell (10^9^/L)        0.025                 1.025                   1.010--1.041     0.001                                      
   Platelet (10^9^/L)                0.001                 1.001                   0.999--1.004     0.309                                      
   HBsAg positive                    -0.079                0.924                   0.614--1.391     0.706                                      
   HBsAb positive                    0.320                 1.377                   0.853--2.226     0.191                                      
   HBeAg positive                    0.399                 1.490                   0.981--2.264     0.062                                      
   HBeAb positive                    -0.090                0.914                   0.591--1.412     0.685                                      
   HBcAb positive                    -0.333                0.717                   0.292--1.761     0.468                                      
  **Tumor Characteristics**                                                                                                                    
   Alpha fetoprotein (ng/ml)         0.000                 1.000                   1.000--1.000     0.112                                      
   Number of nodules                 0.367                 1.444                   1.093--1.906     0.010                                      
   Size of the largest nodule (mm)   0.004                 1.004                   0.999--1.009     0.085                                      
   Portal vein thrombosis            3.602                 36.688                  4.417--304.742   0.001                                      
   Microvascular invasion            0.831                 2.296                   1.651--3.192     0.001   2.988    19.852   2.203--178.917   0.008

**NOTE**. B, intercept; HR, hazard ratio; CI, confidence interval; ALT, alanine aminotranferase; AST, aspartate aminotranferase; γ-GT, γ-glutamyl transferase; PT, prothrombin time; PTA, prothrombin time activity; INR, international normalized ratio; HBsAg, hepatitis B s antigen; HBsAb, hepatitis B s antibody; HBeAg, hepatitis B e antigen; HBeAb, hepatitis B e antibody; HBcAb, hepatitis B c antibody.

Finally, those four independent predictors were added into the original CLIP to construct the SSCLIP. After testing different combinations of possible cut-off values, the cut-off values of age and ALB identified by ROC analysis were included, while the cut-off value of PTA was identified according to Asian-Pacific Association for The Study of Liver Guideline. As a result, patients older than 42 years, with an ALB level ≤ 41.6 g/L, a PTA \< 40%, or MVI were given 1 additional score. The comparison between the original CLIP and the SSCLIP is shown in [Table 4](#pone.0129000.t004){ref-type="table"}.

10.1371/journal.pone.0129000.t004

###### The Original CLIP and the SSCLIP Scoring Systems.

![](pone.0129000.t004){#pone.0129000.t004g}

  Parameters                           Score for the original CLIP   Score for the SSCLIP
  ------------------------------------ ----------------------------- ----------------------
  **CTP class**                                                      
   A                                   0                             0
   B                                   1                             1
   C                                   2                             2
  **Tumor morphology**                                               
   Uninodular and ≤ 50% liver span     0                             0
   Multinodular and ≤ 50% liver span   1                             1
   Massive or \> 50% liver span        2                             2
  **AFP (ng/mL)**                                                    
   \< 400                              0                             0
   ≥ 400                               1                             1
  **Portal vein thrombosis**                                         
   No                                  0                             0
   Yes                                 1                             1
  **Microvascular invasion**                                         
   No                                  \-                            0
   Yes                                 \-                            1
  **Age (years)**                                                    
   ≤ 42                                \-                            0
   \> 42                               \-                            1
  **ALB (g/L)**                                                      
   \> 41.6                             \-                            0
   ≤ 41.6                              \-                            1
  **PTA (%)**                                                        
   ≥ 40                                \-                            0
   \< 40                               \-                            1

**NOTE.** The score range is 0--6 for the original CLIP scoring system, 0--10 for the SSCLIP scoring system.

Comparison between the SSCLIP and Other Models {#sec016}
----------------------------------------------

The ability of the SSCLIP to predict 12-month and 36-month mortality risks was assessed in the training cohort by performing ROC analyses (Fig [2A](#pone.0129000.g002){ref-type="fig"} and [2B](#pone.0129000.g002){ref-type="fig"}). The AUROC was 0.803 for 12-month and 0.756 for 36-month, which were both significantly higher than the AUROCs of original CLIP (0.690 and 0.656), MELD-based CLIP (0.672 and 0.648), Okuda score (0.619 and 0.613) and CTP score (0.530 and 0.607) (all P \< 0.05). When using a best cut-off value of 3 for 12-month prediction and 2 for 36-month prediction, the sensitivities were 73.08% and 76.92% respectively, the specificities were 75.43% and 62.50% respectively, the PPVs were 30.6% and 49.5% respectively and the NPVs were 95.0% and 85.0% respectively ([Table 5](#pone.0129000.t005){ref-type="table"}).

![Comparison of the area under the receiver operating characteristic curve for prediction of mortality among different scoring systems in training cohort (panel A, at 12-month; panel B, at 36-month), and in validation cohort (panel C, at 12-month; panel D, at 36-month).\
P values: (1) Panel A: a vs b = 0.0004; a vs c = 0.0004; a vs d \< 0.0001; a vs e \< 0.0001; (2) Panel B: f vs g \< 0.0001; f vs h \< 0.0001; f vs i \< 0.0001; f vs j = 0.0031; (3) Panel C: k vs l = 0.0020; k vs m = 0.0008; k vs n = 0.0003; k vs o = 0.0418; (4) Panel D: p vs q = 0.0004; p vs r = 0.0008; p vs s = 0.0001; p vs t = 0.0057. AUROC, area under the receiver operating characteristic curve; CI, confidence interval; CLIP, Cancer of The Liver Italian Program; MELD, model for end-stage liver disease; CTP, Child-Turcotte-Pugh.](pone.0129000.g002){#pone.0129000.g002}

10.1371/journal.pone.0129000.t005

###### Diagnostic Accuracy of the SSCLIP Scoring System in the Training Cohort at Cut-off Points and at Different Time Periods.

![](pone.0129000.t005){#pone.0129000.t005g}

             Cut-off point   All patients   Survival   Death    Se % (95% CI)        Sp % (95% CI)        PPV % (95% CI)      NPV % (95% CI)
  ---------- --------------- -------------- ---------- -------- -------------------- -------------------- ------------------- -------------------
  12-month                   n = 201        n = 175    n = 26                                                                 
             ≤3              139            132        7                                                                      
             \>3             62             43         19       73.08 (52.2--88.4)   75.43 (68.4--81.6)   30.6 (19.5--43.8)   95.0 (89.9--98.0)
  36-month                   n = 201        n = 136    n = 65                                                                 
             ≤2              100            85         15                                                                     
             \>2             101            51         50       76.92 (64.8--86.5)   62.50 (53.8--70.6)   49.5 (39.4--59.6)   85.0 (76.5--91.4)

**NOTE.** Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval.

As shown in Fig [2C](#pone.0129000.g002){ref-type="fig"} and [2D](#pone.0129000.g002){ref-type="fig"}, the robustness of the SSCLIP to predict mortality risks was tested externally in the validation cohort. The AUROC was 0.839 for 12-month and 0.776 for 36-month, both of which were still significantly better than the AUROCs of original CLIP (0.718 and 0.678), MELD-based CLIP (0.693 and 0.666), Okuda score (0.653 and 0.633), and CTP score (0.698 and 0.621) (all P \< 0.05).

Prediction of Survival in Different Risk Levels of the SSCLIP {#sec017}
-------------------------------------------------------------

We divided the score of the SSCLIP into three categories, which were low-risk, intermediate-risk and high-risk, standing for SSCLIP score 0\~2, 3\~5 and ≥ 6 respectively. The survival analysis was performed and survival distributions were compared between patients with different risk levels in the SSCLIP. In the training cohort ([Fig 3A](#pone.0129000.g003){ref-type="fig"}), patients in the low-risk level had more favorable survival after surgery than patients in the intermediate-risk level (χ^2^ = 9.221, P = 0.002), while those in high-risk level had poorer outcomes than intermediate-risk patients (χ^2^ = 26.665, P \< 0.001), as well as low-risk patients (χ^2^ = 62.370, P \< 0.001). This condition was confirmed in the validation cohort ([Fig 3B](#pone.0129000.g003){ref-type="fig"}), where low-risk patients had better outcomes than the intermediate-risk group (χ^2^ = 10.166, P = 0.001) and high-risk patients had poorer outcomes than the intermediate-risk patients (χ^2^ = 33.980, P \< 0.001) and the low-risk patients (χ^2^ = 96.050, P \< 0.001).

![Survival distributions of different risk levels of the SSCLIP scoring system in the training cohort (panel A) and validation cohort (panel B).\
Low-risk, intermediate-risk and high-risk represent the SSCLIP score 0\~2, 3\~5 and ≥ 6 respectively.](pone.0129000.g003){#pone.0129000.g003}

Discussion {#sec018}
==========

In this study, we established and validated a SSCLIP scoring system to predict both 12-month and 36-month prognosis of patients who underwent CLR for HCC. To our knowledge, this is the first surgery-specific modified CLIP scoring system that contained variables available in almost each HCC patients. After adding variables that were independent predictors to the original CLIP, the SSCLIP performed significantly better than the original CLIP, the MELD-based CLIP, the Okuda score and the CTP score, with an improvement of 12.6% to 14.4% over the original CLIP, and an improvement of 14.2% to 34.0% over the other predictive models. When divided into three risk levels, the SSCLIP showed a great ability to differentiate survival difference between different risk levels.

As previously known, in the original CLIP scoring system, factors of liver function were united as one item (CTP classification) which only counted for 2 scores at most, while there were three tumor characteristics which counted for 4 scores at the most included in the scoring system. This suggested that the CLIP scoring system mainly focused on tumor characteristics and might attach little weight on underlying liver function or other factors, when the prognosis of HCC might rely on both tumor characteristics and also other contributory factors. In the SSCLIP, we identified 4 more predictors which might provide more information about the patients' status. These predictors, include 1 pathologic parameter, 1 clinical parameter and 2 laboratory parameters, were shown to be highly predictive not only in this study but also in previous studies and clinical practice. Previous studies had identified MVI as an independent risk factor that could affect mortality in patients who received CLR for HCC \[[@pone.0129000.ref013]--[@pone.0129000.ref016]\]. MVI had also proved to be a better predictor of tumor recurrence and overall survival following surgical resection for HCC compared with the Milan criteria which was discriminatory for selecting patients with good outcomes in liver transplantation and surgical resection for HCC \[[@pone.0129000.ref017]\]. In this study, MVI was again found as an independent risk factor and the patient survived in either of the cohorts had a significantly lower rate of MVI, which might indicate that it played an important role in the prognosis of patients who received CLR for HCC. Another factor identified in this study, age, was also an important factor. According to clinical experience, a younger age was usually associated with better liver function and other physical status and might be related to better recovery after surgery. This general observation supported performing the statistical analysis of age in this study. It was also shown by previous studies that a younger age was associated with a better survival rate after 1 year \[[@pone.0129000.ref018]\], and long-term survival rate in elderly patients undergoing hepatectomy for HCC were significantly lower than those in younger patients \[[@pone.0129000.ref015], [@pone.0129000.ref019]--[@pone.0129000.ref021]\]. In addition, we also found that the ALB level to be an independent predictor, which agreed with previous studies \[[@pone.0129000.ref022]--[@pone.0129000.ref026]\]. This was consistent with the fact that a declined ALB level could reflect liver dysfunction as ALB was synthesized in the liver. PTA level was another laboratory parameter we found to be an independent predictor. Previous studies had shown that the PTA level had an independent predictive value for the development and survival of HCC \[[@pone.0129000.ref027]--[@pone.0129000.ref029]\], and it is also widely accepted that the PTA level could reflect the levels of blood coagulation factors synthesized in the liver, that is, a lower PTA level might represent a poorer liver function.

In addition to identifying predictors to construct the SSCLIP, we also divided the score of the SSCLIP into three categories to represent different risk levels. As shown in [Fig 3](#pone.0129000.g003){ref-type="fig"}, survival rates were significantly higher in low-risk patients than in the other two levels whereas high-risk patients showed the lowest survival rates. This stratification of scores would be particularly useful in clinical practice because it may differentiate patients with a different prognosis and may guide the physician in choosing the most appropriate treatment or health care regime after surgery.

To date, most of the prognostic models of HCC have not been validated, partly because it is generally harder for a prognostic model to perform well in external cohorts than in the cohort from which it was derived. However, to ensure that the model could be applied in a wide range of patients, it was important to check the stability and reliability of the scoring system's prognostic ability in different populations by performing external validation. In this study, we performed validation of the SSCLIP and generated data demonstrating the model's good prognostic ability in an external cohort consisting of four independent medical centers. This finding strongly suggests that the SSCLIP is capable of being applied to a wide range of patients who underwent CLR for HCC.

There are, however, some limitations of this study. First, apart from the factors involved in this study, there might be other factors that were associated with the prognosis of HCC patients who underwent CLR. We regret that we were not able to involve all the potential factors in this retrospective study, especially some unusual factors that require special detection techniques. Nevertheless, since we intended to propose a practical and objective model, it was better to construct the SSCLIP with factors which could be easily assessed and would not be affected by subjective judgments. Secondly, the SSCLIP was derived from a population with included a majority of HBV-related HCC patients (including superinfection of HBV and HCV). Further studies are required to validate this model in populations where HCV, alcohol, non-alcoholic fatty liver disease, or other etiologies predominate. Thirdly, we also acknowledge that prospective studies with longer-term follow-up are needed to further extend the assessment of the SSCLIP's performance.

In summary, we have established the first scoring system that was specific to patients who underwent CLR based on the CLIP with widely available variables. The SSCLIP scoring system may prove to be an ideal model useful in both epidemiologic research and in clinical practice for patient counseling and prognosis evaluation.
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